Next 10 |
2024-04-23 13:32:13 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi succeeds in late-stage trial for ...
2024-04-23 11:37:17 ET Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from ...
2024-04-22 12:03:46 ET More on GSK, Sanofi, etc. GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) GSK shingles vaccine shown 82% ...
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-19 07:03:48 ET Summary Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sales of next-generation drugs such as Ngenla, Bosul...
2024-04-19 04:02:55 ET Summary GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate the effectiveness and efficiency of its pipelin...
2024-04-17 13:26:33 ET More on GSK GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy GSK plc (GSK) Q4 2023 Earnings Call Transcript GSK, Pfizer-backed ViiV gets FDA oka...
2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-04-16 18:25:52 ET Summary Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results ...
2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...
News, Short Squeeze, Breakout and More Instantly...
GlaxoSmithKline PLC Company Name:
GSK Stock Symbol:
NYSE Market:
Drug shortages in the UK have more than doubled between 2020 and 2023, a recent study by the Nuffield Trust reveals. Brexit is cited as a significa...
Anne Wojcicki, co-founder and chief executive of 23andMe Holding Co (NASDAQ:ME), is contemplating taking the genetics testing compan...
Wednesday, GSK plc (NYSE:GSK) revealed data from the ZOSTER-049 long-term follow-up phase 3 trial, which followed participants ...